Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 23 (SCARNA23)
- Target
- SCARNA23
- Molecular classification
- Small Cajal body-specific RNA (scaRNA), Non-coding RNA, Box H/ACA RNA
01
Overview
Small Cajal body-specific RNA 23 (SCARNA23) is a non-coding RNA of the box H/ACA class, specifically localized to Cajal bodies within the nucleus. SCARNA23 is believed to guide the post-transcriptional modification of spliceosomal RNAs transcribed by RNA polymerase II, most notably U1 small nuclear RNA, through pseudouridylation (the conversion of uridine to pseudouridine)[2][1][7]. Like other scaRNAs, SCARNA23 plays an essential role in the maturation and modification of snRNAs necessary for mRNA splicing in eukaryotic cells[1][5]. While no direct involvement in disease or therapeutics is currently documented for SCARNA23, similar molecules have shown relevance as cancer biomarkers[4][6].
- Other names
- ACA12ACA12 scaRNASCARNA23Small Cajal body-specific RNA 23
02
Biological functions
RNA modification (pseudouridylation, isomerization of uridine to pseudouridine)Post-transcriptional modification of spliceosomal RNAs (especially U1 spliceosomal RNA)
03
Disease associations
Other (No direct disease associations identified for SCARNA23; however, similar scaRNAs and snoRNAs have been implicated as molecular markers in cancer)
Beyond the preview
Go deeper on Small Cajal body-specific RNA 23 (SCARNA23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Small Cajal body-specific RNA 23 (SCARNA23).